Imatinib-induced gastrointestinal vascular ectasia in a patient with advanced GIST: Case report and literature review

7Citations
Citations of this article
14Readers
Mendeley users who have this article in their library.

Abstract

Background: Imatinib is generally well tolerated in the treatment of advanced gastrointestinal stromal tumors (GIST). Gastrointestinal vascular ectasia (GIVE) and gastric antral vascular ectasia (GAVE), while rare, are significant under-reported complications of imatinib therapy. Case Report: We present one patient with GIVE complicating imatinib therapy with a literature review of this rare side-effect. Results: A 68-year-old woman was diagnosed with advanced GIST, wild-type CKIT. After 3 months of treatment with imatinib, she had partial response. However, she was diagnosed with GAVE and, later, also with GIVE. During her 3-year imatinib treatment, she suffered from severe anemia and required blood transfusions. Conservative treatments were not helpful and the ectatic lesions resolved only with cessation of imatinib. Conclusion: This confirms a causal relationship between GIVE and imatinib. GIVE and GAVE should be considered possible causes of anemia and upper gastrointestinal bleeding in patients receiving imatinib therapy.

Cite

CITATION STYLE

APA

Abu-Amna, M., Awadie, H., & Bar-Sela, G. (2016). Imatinib-induced gastrointestinal vascular ectasia in a patient with advanced GIST: Case report and literature review. Anticancer Research, 36(11), 6151–6154. https://doi.org/10.21873/anticanres.11206

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free